Turnover for the year to December 31 rose 43% to £30.2mln, while underlying earnings (EBITDA) were up 39% at £3.4mln.
The company’s “backlog”, which is essentially its pipeline of new business, stands at around £59mln.
This means the company has booked 85% of planned 2016 sales already.
Ergomed is sitting on cash of £4mln with zero debt.
The firm is a hybrid. It is a pharma services firm that also takes a stake in drugs during the development process.
That means it has a steady and growing income base, plus the kick that comes with a successful treatment making its way through the clinical trials.
It now has a pipeline of six prospective products in co-development that underpin the value of the business.
It is looking to bring two new drug candidates into the portfolio per annum.
This year analysts are expecting significant news from Ergomed's existing partners, including phase III results of Aeterna Zentaris's Zoptrex product for endometrial cancer and Phase IIa results of Ferrer's insomnia treatment lorediplon.
“Our co-development business continues to gain traction with another programme added in 2015 and important data expected from two of our five co-development partners during 2016," said chief executive Miroslav Reljanovic.